Joseph B Lerman1, Aditya A Joshi1, Abhishek Chaturvedi1, Tsion M Aberra1, Amit K Dey1, Justin A Rodante1, Taufiq Salahuddin1, Jonathan H Chung1, Anshuma Rana1, Heather L Teague1, Jashin J Wu1, Martin P Playford1, Benjamin A Lockshin1, Marcus Y Chen1, Veit Sandfort1, David A Bluemke1, Nehal N Mehta2. 1. From National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD (J.B.L., A.A.J., A.C., T.M.A., A.K.D., J.A.R., T.S., J.H.C., A.R., H.L.T., M.P.P., M.Y.C., V.S., D.A.B., N.N.M.); Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, CA (J.J.W.); and DermAssociates, Silver Spring, MD (B.A.L.). 2. From National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD (J.B.L., A.A.J., A.C., T.M.A., A.K.D., J.A.R., T.S., J.H.C., A.R., H.L.T., M.P.P., M.Y.C., V.S., D.A.B., N.N.M.); Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, CA (J.J.W.); and DermAssociates, Silver Spring, MD (B.A.L.). nehal.mehta@nih.gov.
Abstract
BACKGROUND: Psoriasis, a chronic inflammatory disease associated with an accelerated risk of myocardial infarction, provides an ideal human model to study inflammatory atherogenesis in vivo. We hypothesized that the increased cardiovascular risk observed in psoriasis would be partially attributable to an elevated subclinical coronary artery disease burden composed of noncalcified plaques with high-risk features. However, inadequate efforts have been made to directly measure coronary artery disease in this vulnerable population. As such, we sought to compare total coronary plaque burden and noncalcified coronary plaque burden (NCB) and high-risk plaque (HRP) prevalence between patients with psoriasis (n=105), patients with hyperlipidemia eligible for statin therapy under National Cholesterol Education Program-Adult Treatment Panel III guidelines (n=100) who were ≈10 years older, and healthy volunteers without psoriasis (n=25). METHODS: Patients underwent coronary computed-tomography angiography for total coronary plaque burden and NCB quantification and HRP identification, defined as low attenuation (<30 hounsfield units), positive remodeling (>1.10), and spotty calcification. A consecutive sample of the first 50 patients with psoriasis was scanned again 1 year after therapy. RESULTS: Despite being younger and at lower traditional risk than patients with hyperlipidemia, patients with psoriasis had increased NCB (mean±SD: 1.18±0.33 versus 1.11±0.32, P=0.02) and similar HRP prevalence (P=0.58). Furthermore, compared to healthy volunteers, patients with psoriasis had increased total coronary plaque burden (1.22±0.31 versus 1.04±0.22, P=0.001), NCB (1.18±0.33 versus 1.03±0.21, P=0.004), and HRP prevalence beyond traditional risk (odds ratio, 6.0; 95% confidence interval, 1.1-31.7; P=0.03). Last, among patients with psoriasis followed for 1 year, improvement in psoriasis severity was associated with improvement in total coronary plaque burden (β=0.45, 0.23-0.67; P<0.001) and NCB (β=0.53, 0.32-0.74; P<0.001) beyond traditional risk factors. CONCLUSIONS: Patients with psoriasis had greater NCB and increased HRP prevalence than healthy volunteers. In addition, patients with psoriasis had elevated NCB and equivalent HRP prevalence as older patients with hyperlipidemia. Last, modulation of target organ inflammation (eg, skin) was associated with an improvement in NCB at 1 year, suggesting that control of remote sites of inflammation may translate into reduced coronary artery disease risk.
BACKGROUND:Psoriasis, a chronic inflammatory disease associated with an accelerated risk of myocardial infarction, provides an ideal human model to study inflammatory atherogenesis in vivo. We hypothesized that the increased cardiovascular risk observed in psoriasis would be partially attributable to an elevated subclinical coronary artery disease burden composed of noncalcified plaques with high-risk features. However, inadequate efforts have been made to directly measure coronary artery disease in this vulnerable population. As such, we sought to compare total coronary plaque burden and noncalcified coronary plaque burden (NCB) and high-risk plaque (HRP) prevalence between patients with psoriasis (n=105), patients with hyperlipidemia eligible for statin therapy under National Cholesterol Education Program-Adult Treatment Panel III guidelines (n=100) who were ≈10 years older, and healthy volunteers without psoriasis (n=25). METHODS:Patients underwent coronary computed-tomography angiography for total coronary plaque burden and NCB quantification and HRP identification, defined as low attenuation (<30 hounsfield units), positive remodeling (>1.10), and spottycalcification. A consecutive sample of the first 50 patients with psoriasis was scanned again 1 year after therapy. RESULTS: Despite being younger and at lower traditional risk than patients with hyperlipidemia, patients with psoriasis had increased NCB (mean±SD: 1.18±0.33 versus 1.11±0.32, P=0.02) and similar HRP prevalence (P=0.58). Furthermore, compared to healthy volunteers, patients with psoriasis had increased total coronary plaque burden (1.22±0.31 versus 1.04±0.22, P=0.001), NCB (1.18±0.33 versus 1.03±0.21, P=0.004), and HRP prevalence beyond traditional risk (odds ratio, 6.0; 95% confidence interval, 1.1-31.7; P=0.03). Last, among patients with psoriasis followed for 1 year, improvement in psoriasis severity was associated with improvement in total coronary plaque burden (β=0.45, 0.23-0.67; P<0.001) and NCB (β=0.53, 0.32-0.74; P<0.001) beyond traditional risk factors. CONCLUSIONS:Patients with psoriasis had greater NCB and increased HRP prevalence than healthy volunteers. In addition, patients with psoriasis had elevated NCB and equivalent HRP prevalence as older patients with hyperlipidemia. Last, modulation of target organ inflammation (eg, skin) was associated with an improvement in NCB at 1 year, suggesting that control of remote sites of inflammation may translate into reduced coronary artery disease risk.
Authors: Nehal N Mehta; YiDing Yu; Rebecca Pinnelas; Parasuram Krishnamoorthy; Daniel B Shin; Andrea B Troxel; Joel M Gelfand Journal: Am J Med Date: 2011-08 Impact factor: 4.965
Authors: Markella V Zanni; Suhny Abbara; Janet Lo; Bryan Wai; David Hark; Eleni Marmarelis; Steven K Grinspoon Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Mathijs O Versteylen; Bas L Kietselaer; Pieter C Dagnelie; Ivo A Joosen; Admir Dedic; Rolf H Raaijmakers; Joachim E Wildberger; Koen Nieman; Harry J Crijns; Wiro J Niessen; Mat J Daemen; Leonard Hofstra Journal: J Am Coll Cardiol Date: 2013-04-03 Impact factor: 24.094
Authors: Kazuyuki Yahagi; Frank D Kolodgie; Fumiyuki Otsuka; Aloke V Finn; Harry R Davis; Michael Joner; Renu Virmani Journal: Nat Rev Cardiol Date: 2015-10-27 Impact factor: 32.419
Authors: Alexander V Sorokin; Kazuhiko Kotani; Youssef A Elnabawi; Amit K Dey; Aparna P Sajja; Shingo Yamada; Masashi Ueda; Charlotte L Harrington; Yvonne Baumer; Justin A Rodante; Joel M Gelfand; Marcus Y Chen; Aditya A Joshi; Martin P Playford; Alan T Remaley; Nehal N Mehta Journal: Circ Res Date: 2018-11-09 Impact factor: 17.367
Authors: Michael S Garshick; Tessa J Barrett; Todd Wechter; Sarah Azarchi; Jose U Scher; Andrea Neimann; Stuart Katz; Judilyn Fuentes-Duculan; Maria V Cannizzaro; Sanja Jelic; Edward A Fisher; James G Krueger; Jeffrey S Berger Journal: Arterioscler Thromb Vasc Biol Date: 2019-04 Impact factor: 8.311
Authors: Amit K Dey; Ranjitha Gaddipati; Youssef A Elnabawi; Emily Ongstad; Aditya Goyal; Jonathan H Chung; Heather L Teague; Justin A Rodante; Aparna A Sajja; Alexander V Sorokin; Sundus S Lateef; Milena Aksentijevich; Harry Choi; Aarthi S Reddy; Nevin J Varghese; Jacob Groenendyk; Agastya D Belur; Leonard Genovese; Joshua P Rivers; Joseph Lerman; Mohammad Tarek Kabbany; Charlotte Harrington; Jenis Ortiz; Noor Khalil; Andrew Keel; Yvonne Baumer; Marcus Y Chen; David A Bluemke; Aditya A Joshi; Mariana J Kaplan; Alan T Remaley; Martin P Playford; Sotirios K Karathanasis; Joel M Gelfand; Ruchi Gupta; Nehal N Mehta Journal: JAMA Dermatol Date: 2020-02-01 Impact factor: 10.282
Authors: Zbigniew Siudak; Kalina Wysocka-Dubielecka; Krzysztof Malinowski; Artur Dziewierz; Tomasz Tokarek; Krzysztof Plens; Dariusz Dudek Journal: Cardiol J Date: 2018-08-29 Impact factor: 2.737
Authors: Martin P Playford; Amit K Dey; Claudia Zierold; Aditya A Joshi; Frank Blocki; Fabrizio Bonelli; Justin A Rodante; Charlotte L Harrington; Joshua P Rivers; Youssef A Elnabawi; Marcus Y Chen; Mark A Ahlman; Heather L Teague; Nehal N Mehta Journal: Atherosclerosis Date: 2019-08-17 Impact factor: 5.162
Authors: Philip M Carlucci; Monica M Purmalek; Amit K Dey; Yenealem Temesgen-Oyelakin; Simantini Sakhardande; Aditya A Joshi; Joseph B Lerman; Alice Fike; Michael Davis; Jonathan H Chung; Martin P Playford; Mohammad Naqi; Pragnesh Mistry; Gustavo Gutierrez-Cruz; Stefania Dell'Orso; Faiza Naz; Taufiq Salahuddin; Balaji Natarajan; Zerai Manna; Wanxia L Tsai; Sarthak Gupta; Peter Grayson; Heather Teague; Marcus Y Chen; Hong-Wei Sun; Sarfaraz Hasni; Nehal N Mehta; Mariana J Kaplan Journal: JCI Insight Date: 2018-04-19
Authors: Scott M Gordon; Jonathan H Chung; Martin P Playford; Amit K Dey; Denis Sviridov; Fayaz Seifuddin; Yun-Ching Chen; Mehdi Pirooznia; Marcus Y Chen; Nehal N Mehta; Alan T Remaley Journal: Atherosclerosis Date: 2018-09-25 Impact factor: 5.162